PARIS, France—With renal denervation on the cusp of gaining a place in clinical practice for the treatment of hypertension, researchers are looking more closely at other conditions associated with ...

The treatment of resistant hypertension has received a boost with the recent US Food and Drug Administration (FDA) approval of a completely new therapeutic approach that reduces activity in the ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. First, let me ...

In June 2026, Medtronic drew attention as analysts emphasized its positioning in cardiac ablation, diabetes care and ...

Renal denervation received a much-needed shot in the arm after favorable data on the procedures for uncontrolled hypertension were released at the recent Transcatheter Cardiovascular Therapeutics ...

Add Yahoo as a preferred source to see more of our stories on Google. TUPELO — High blood pressure, or hypertension, is the top preventable cause of strokes and heart attacks in the United States, ...

Part 1 explained the concept behind renal denervation and detailed early evidence for the therapy’s effectiveness in treating drug-resistant hypertension. In Part 2, the story continues with a ...

Medtronic suffered yet another disappointment in its relentless pursuit of bringing renal denervation to market for people living with uncontrolled high blood pressure. There seems to be no question ...

Medtronic gains attention as renal denervation optimism, revenue growth, cardiac care, and diabetes technology reshape its ...

With 60 hedge funds holding bullish positions and analysts seeing 19.84% upside potential, Medtronic plc (NYSE:MDT) ranks among the top stocks to buy for financial stability. Medtronic plc (NYSE:MDT) ...